Alignment Healthcare (NASDAQ:ALHC) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Alignment Healthcare (NASDAQ:ALHC) issued its earnings results on Thursday. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04, FiscalAI reports. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.22 billion. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.Alignment Healthcare’s quarterly revenue was up 33.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.05) EPS.

Here are the key takeaways from Alignment Healthcare’s conference call:

• Membership grew ~31% YoY to 284,800, revenue rose 33% to $1.2B and Adjusted EBITDA increased 88% to $38M — results beat guidance and management raised full?year revenue and profitability ranges.
• Management highlighted material operational progress — claims auto?adjudication improved from <15% to >60% YTD — and is investing in AI, contract automation and talent to drive further scale and margin expansion.
• A CMS rule change exposed an internal workflow error that caused the company to pay acute rates instead of observation in January (about a $2M impact that cannot be clawed back); the process was corrected by end of February.
• Full?year and Q2 guidance incorporate higher inpatient admissions per 1,000 driven by intentional growth in higher?acuity D?SNP/LIS/dual members and a cautious risk?adjustment stance for new members, with potential upside from later CMS “sweeps.”

Alignment Healthcare Price Performance

NASDAQ ALHC traded down $2.93 on Friday, hitting $19.62. 7,301,449 shares of the company were exchanged, compared to its average volume of 3,170,969. The firm has a 50 day moving average of $19.38 and a two-hundred day moving average of $19.42. The company has a market cap of $4.06 billion, a P/E ratio of -1,961.44, a P/E/G ratio of 4.46 and a beta of 1.20. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 1.80. Alignment Healthcare has a 1-year low of $11.63 and a 1-year high of $23.87.

Key Headlines Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q1 results beat expectations — GAAP EPS was $0.05 vs. a $0.01 consensus and revenue was $1.24B (up ~33% year-over-year). Management said the quarter showed margin expansion and disciplined growth, which supports revenue momentum and the growth story. Press Release
• Positive Sentiment: Analyst sentiment turned more favorable — Zacks upgraded ALHC from Hold to Strong Buy, which could support buying interest among momentum and retail investors. Zacks Upgrade
• Neutral Sentiment: Company provided revenue guidance for Q2 (~$1.3B) and FY2026 (~$5.2B) roughly in line with consensus, but EPS guidance detail was limited in the public notices — mixed signal for investors seeking clarity on near-term profitability. Press Release / Guidance
• Neutral Sentiment: Full Q1 earnings call transcript is available with management commentary — useful for investors wanting detail on membership trends, medical-loss assumptions and margin drivers that will determine whether growth is sustainable. Earnings Call Transcript
• Negative Sentiment: Stock sold off sharply after the print — reports show a roughly 10% after-hours decline and heavier trading volume, indicating the beat did not fully reassure investors. That immediate selling suggests concerns about forward earnings visibility or other forward-looking metrics. After-Hours Drop
• Negative Sentiment: Key profitability/financial ratios remain a concern — ALHC still shows a very slim/negative net margin and modest returns on equity; leverage (debt-to-equity ~1.8) and valuation metrics may keep some investors cautious despite top-line growth. Earnings Snapshot & Metrics

Insider Transactions at Alignment Healthcare

In other news, President Dawn Christine Maroney sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $20.87, for a total transaction of $626,100.00. Following the transaction, the president directly owned 1,028,813 shares in the company, valued at approximately $21,471,327.31. This represents a 2.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John E. Kao sold 82,299 shares of the stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $20.80, for a total transaction of $1,711,819.20. Following the sale, the chief executive officer directly owned 1,806,641 shares in the company, valued at $37,578,132.80. This trade represents a 4.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 1,474,097 shares of company stock worth $28,679,550. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Summit Securities Group LLC acquired a new stake in shares of Alignment Healthcare in the 4th quarter valued at $26,000. Larson Financial Group LLC acquired a new position in shares of Alignment Healthcare during the third quarter valued at $33,000. Parallel Advisors LLC lifted its stake in shares of Alignment Healthcare by 87.7% during the fourth quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock valued at $33,000 after acquiring an additional 773 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Alignment Healthcare in the third quarter valued at about $53,000. Finally, Wexford Capital LP bought a new position in Alignment Healthcare in the third quarter valued at about $164,000. Institutional investors and hedge funds own 86.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Monday, April 20th. Robert W. Baird set a $28.00 price objective on Alignment Healthcare in a report on Friday, January 30th. Zacks Research raised shares of Alignment Healthcare from a “hold” rating to a “strong-buy” rating in a report on Tuesday. TD Cowen increased their target price on shares of Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.89.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.